Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: An observational cohort Study

Journal of General Internal Medicine

Volumn 28, Issue 5, 2013, Pages 691-697

  Nichols, Gregory A ^a   Joshua Gotlib, Sandra ^b   Parasuraman, Shreekant ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Blood pressure control; Cholesterol control; CVD risk factors; Glycemic control

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEPRESSION; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ICD-9-CM; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY; SYSTOLIC BLOOD PRESSURE; ADULT; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OREGON; RISK FACTORS;

EID: 84892949649     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-012-2320-1     Document Type: Article

References (33)

1. American Diabetes Association. Standards of medical care in diabetes- 2012. Diabetes Care. 2012;35(Suppl 1):S11-S63.
2. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
3. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
4. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
5. Stratton IM, Alder AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321(7258):405-412.
6. Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: A nested case-control study. Diabetes Care. 2011;34(1):77-83.
7. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800-811.
8. Grundy SM, Cleeman JI, Bairey-Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
9. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Working Group report on hypertension in diabetes. Hypertension. 1994;23(2):145-158.
10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
11. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-172.
12. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes trials. Diabetes Care. 2009;32(1):187-192.
13. Stratton IM, Matthews DR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia. 2006;49:1761- 1769.
14. Gudbjornsdotir S, Eliasson B, Eeg-Olofsson K, Zethelius B, Cederholm J. on behalf of the National Diabetes Register (NDR). Additive effoects of glycaemia and dyslipidemia on risk of cardiovascular disease in type 2 diabetes: An observational study from the Swedish National Diabetes Register. Diabetologia. 2011;54:2544-2551.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130 (6):461-470.
16. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068-2074.
17. Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjornsdottir S, et al. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diab Res Clin Pract. 2009;86:74-81.
18. Gaede P, Lund-Anderson H, Parving HH, Pederson O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
19. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in type 2 diabetes: A patient-centered approach. Diabetes Care. 2012;35(6):1364-1379.
20. UKPDS Group. UKPDS 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet. 1998;352:837- 851.
21. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-430.
22. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdotir S, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: An observational study for the Swedish National Diabetes Register (NDR). J Intern Med. 2010;268 (5):471-482.
23. Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: A large prospective cohort study. Diabet Med. 2008;25:1295-1301.
24. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: A retrospective cohort study. Lancet. 2010;375(9713):481-489.
25. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: Evidence of glycaemic thresholds. Diabetologia. 2012;55(3):636-643.
26. Jorgensen CH, Gislason GH, Bretler D, Sorensen R, Norgaard ML, Hansen ML, et al. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction - A nationwide study. Int J Cardiol. 2011;152(3):327-331.
27. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med. 2008;168(19):2070-2080.
28. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2011;57(20):2037-114.
29. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585.
30. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61-68.
31. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: Subgroup analyses from the ONTARGET (ONgoing telmisartan alone and in combination with ramipril global endpoint trial). J Am Coll Cardiol. 2012;59(1):74-83.
32. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: A population study of 3.3 million people. Circulation. 2008;117(15):1945-1954.
33. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512-1524.